ClinicalTrials.gg
CompletedNCT06104124Updated Oct 29, 2026

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

A Phase 3 interventional study of Dazodalibep and Placebo in Sjogren's Syndrome, sponsored by Amgen. Completed at 206 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
651
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
5th of 76
651 · median 57
Started
2024
with 8 others
Phase 3
12 of 111
3 open now
Registered
90th of 111
by date
Lead sponsor
7 of 111
Amgen

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 5th largest by enrollment of the 76 interventional ones that give a count, is one of 9 that started in 2024, is one of 12 in phase 3, and was the 90th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity.

Secondary Objectives:

  1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS.
  2. To evaluate the safety and tolerability of dazodalibep in participants with SS
Read the detailed description

Acquired from Horizon in 2024.

03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

Keywords

  • Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity Study Phase: Phase 3
  • European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI)
  • European Alliance of Associations for Rheumatology Sjögren's Syndrome Patient Reported Index (ESSPRI)
  • European Alliance of Associations for Rheumatology (EULAR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with Sjögren's syndrome (SS) by meeting the 2016 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) Classification Criteria.
  • Have an European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) score of >= 5 despite symptomatic or local therapy at screening.
  • Positive for either anti-Ro autoantibodies or rheumatoid factor (RF), or both at screening (as per the central laboratory test).

Key Exclusion Criteria:

  • Medical history of confirmed deep vein thrombosis, pulmonary embolism, or arterial thromboembolism within 2 years of screening.
  • Active or history of malignancy within the last 5 years, except in situ carcinoma of cervix treated with apparent success with curative therapy > 12 months prior to screening OR cutaneous basal cell carcinoma following presumed curative therapy.
  • Individuals with any severe or life-threatening cardiovascular (including vasculitis), respiratory, endocrine, gastrointestinal, hematological, psychiatric, or systemic disorder or any other condition that would place the individual at unacceptable risk of complications, interfere with evaluation of the IP, or confound the interpretation of participant safety or study results.
  • Individuals who have a positive test for , , or infection. A positive test for hepatitis B at screening is defined as: (1) positive for HBsAg OR (2) positive for either HBcAb or HBsAb and HBV DNA detected above the LLOQ by reflex testing by the central laboratory at screening.
  • Active TB or untreated (per local guidelines) latent TB
  • Individuals with a history of more than one episode of herpes zoster and/or any opportunistic infection in the last 12 months, and active infection requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring intravenous (IV) antibiotics within 12 months prior to screening.
  • Individuals who have received a live (attenuated) vaccine within the 4 weeks prior to randomization or plan to receive a during their participation in the study.
  • Last administration of experimental or biologic or oral agents \< 6 months prior to screening.
  • Individuals who have had previous treatment with any biologic B-cell-depleting therapy (eg, rituximab, ocrelizumab, inebilizumab, ofatumumab, or ianalumab) within 12 months or other B-cell-targeting therapy (eg, belimumab) \< 3 months prior to screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
651 participants (actual)

Study arms

  • Experimental
    Dazodalibep Dose 1

    Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.

    Drug: Dazodalibep

  • Experimental
    Dazodalibep Dose 2

    Participants will be administered dose 2 of dazodalibep by IV infusion.

    Drug: Dazodalibep

  • Placebo comparator
    Placebo

    Participants will be administered placebo by IV infusion.

    Drug: Placebo

Interventions

  • IV infusion

    Also known as: VIB 4920, MEDI 4920

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Change from baseline in European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) Score

    Time frame: At Week 48

Secondary outcomes

  1. Proportion of participants achieving ESSDAI response

    Time frame: At Week 48

  2. Change from baseline in Diary for Assessing Sjogren's Patient-Reported Outcome Index (DASPRI) dryness domain score

    Time frame: At Week 48

  3. Change from baseline in ESSPRI dryness domain score

    Time frame: At Week 48

  4. Change from baseline in DASPRI dryness domain score

    Time frame: At Week 48

  5. Change from baseline in tender and swollen joint counts

    Time frame: At Week 48

  6. Change from baseline in Patient-Reported Outcomes Measurement Information System Fatigue-Short Form 10a (PROMIS-Fatigue-SF-10a)

    Time frame: At Week 48

  7. Change from baseline in ESSDAI score

    Time frame: Week 12 and Week 24

  8. Change from baseline in DASPRI total score

    Time frame: At Week 48

  9. Change from baseline in ESSPRI total score

    Time frame: At Week 48

  10. Change from baseline in total stimulated salivary flow

    Time frame: At Week 48

  11. Number of participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline (Day 1) to Week 56

  12. Number of participants With Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: Up to Week 56

  13. Number of participants With Adverse Events of Special Interest (AESIs)

    Time frame: Up to Week 56

07

Study locations

206 sites
  • Arizona Arthritis & Rheumatology Associates - Avondale
    Avondale, Arizona 85392, United States
  • Arizona Research Clinic PLLC
    Chandler, Arizona 85225-2915, United States
  • Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln
    Flagstaff, Arizona 86001-6299, United States
  • Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St
    Gilbert, Arizona 85297-7338, United States
  • Arizona Arthritis and Rheumatology Associates - Glendale - 5681 W Beverly Ln
    Glendale, Arizona 85306-9800, United States
  • Arizona Arthritis and Rheumatology Associates - Tucson - 2001 W Orange Grove Rd
    Tucson, Arizona 85704-1140, United States
  • UCSD Altman Clinical and Translational Research Institute Building
    La Jolla, California 92037-1337, United States
  • Inland Rheumatology Clinical Trials Incorporated
    Upland, California 91786-4951, United States
  • Tekton Research, LLC - 2121 E Harmony Rd - PPDS
    Fort Collins, Colorado 80528-3404, United States
  • Bradenton Research Center Inc
    Bradenton, Florida 34205-1704, United States
  • Clinical Research of West Florida Inc - Clearwater
    Clearwater, Florida 33765-2616, United States
  • West Broward Rheumatology Associates, Inc.
    Tamarac, Florida 33321-2956, United States
  • BayCare Medical Group
    Tampa, Florida 33614-7101, United States
  • Augusta University Medical Center-Augusta-1120 15th St
    Augusta, Georgia 30912-0004, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160-0001, United States
  • Massachusetts General Hospital (MGH) - Rheumatology Associates
    Boston, Massachusetts 02114-2621, United States
  • Clinical Research Institute of Michigan, LLC-St. Claire Shores
    Saint Clair Shores, Michigan 48081, United States
  • Kansas City Physician Partners-8350 N Saint Clair Ave
    Kansas City, Missouri 64151-5100, United States
  • Arthritis, Rheumatic & Bone Disease Associates - Voorhees
    Voorhees Township, New Jersey 08043-4509, United States
  • NYU Langone Health - Joseph S. and Diane H. Steinberg Ambulatory Care Center
    Brooklyn, New York 11201-5501, United States
  • Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 801 E Morehead St
    Charlotte, North Carolina 28202, United States
  • Duke Early Phase Clinical Research Unit - PPDS
    Durham, North Carolina 27710-0001, United States
  • Onsite Clinical Solutions, LLC - Salisbury
    Salisbury, North Carolina 28144, United States
  • University of Toledo Medical Center
    Toledo, Ohio 43614-2595, United States
  • STAT Research-600 Aviator Ct
    Vandalia, Ohio 45377-9474, United States
  • Low Country Rheumatology PA-Summerville
    Summerville, South Carolina 29486-7887, United States
  • Murfreesboro Medical Clinic Westlawn
    Murfreesboro, Tennessee 37128, United States
  • Amarillo Center For Clinical Research
    Amarillo, Texas 79124-1601, United States
  • Tekton Research, LLC - W Gate Blvd - Austin - PPDS
    Austin, Texas 78745-1470, United States
  • Accurate Clinical Management-Baytown
    Baytown, Texas 77521, United States
  • Cedar Health Research - Arlington - PPDS
    Euless, Texas 76040, United States
  • R & H Clinical Research - Katy - 1531 Westborough Dr
    Katy, Texas 77449, United States
  • Valley Arthritis Center
    McAllen, Texas 78501, United States
  • University of Texas - San Antonio - Health Science Center - PPDS
    San Antonio, Texas 78229-3901, United States
  • DM Clinical Research - Migraine and COPD - PPDS
    Tomball, Texas 77375, United States
  • Overlake Arthritis & Osteoporosis Center
    Bellevue, Washington 98004-3016, United States
  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801-2805, United States
  • Sanatorio Agote - Swiss Medical Group - PPDS
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1425EOE, Argentina
  • Framingham Centro Médico
    La Plata, Buenos Aires B1900, Argentina
  • Instituto CER S.A.
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Instituto de Investigaciones Clinicas Quilmes SRL
    Quilmes, Buenos Aires B1878GEG, Argentina
  • MR Medicina Reumatologica
    San Fernando, Buenos Aires B1646GHP, Argentina
  • Hospital General de Agudos Dr. José María Ramos Mejia
    Buenos Aires, Ciudad Autónoma de BuenosAires C1121ADC, Argentina
  • Expertia S.A- Mautalén Salud e Investigación
    Buenos Aires, Ciudad Autónoma de BuenosAires C1128AAF, Argentina
  • Centro Privado de Medicina Familiar
    Buenos Aires, Ciudad Autónoma de BuenosAires C1417, Argentina
  • Consultorios Médicos Dr. Doreski - Fundacion Respirar - PPDS
    Buenos Aires, Ciudad Autónoma de BuenosAires C1426ABP, Argentina
  • Sanatorio Allende S.A
    Córdoba, Córdoba Province X5000JHGQ, Argentina
  • Centro de Investigaciones Médicas Tucumán - PPDS
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Centro de Investigaciones Reumatológicas
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Clínica Mayo de U.M.C.B. S.R.L
    San Miguel de Tucumán, Tucumán Province T4000IHE, Argentina
  • DOM Centro de Reumatología
    Buenos Aires, C1111AAH, Argentina
  • Aprillus Asistencia e Investigacion de Arcis Salud SRL
    Buenos Aires, C1406AGA, Argentina
  • Centro Medico Arsema
    Buenos Aires, C1427CCL, Argentina
  • Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
    San Juan, J5400DIL, Argentina
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • UZ Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • SER - Serviços Especializados em Reumatologia da Bahia S/S - ME
    Salvador, Estado de Bahia 40150-150, Brazil
  • AES - AS - L2IP - Instituto de Pesquisas Clínicas LTDA Brasilia
    Brasília, Federal District 70200-730, Brazil
  • Irmandade da Santa Casa de Misericórdia de Belo Horizonte - PPDS
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Centro de Estudos em Terapias Inovadoras
    Curitiba, Paraná 80030-110, Brazil
  • LMK Servicos Medicos SS
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Centre de Recherche Musculo-Squelettique - 1920 Rue Bellefeuille
    Trois-Rivières, Quebec G9A 3X2, Canada
  • Centro de especialidades médicas Vanguardia
    Temuco, Araucania 4780000, Chile
  • Clinical Research Chile SpA - PPDS
    Valdivia, Los Ríos Region 5110683, Chile
  • Enroll SpA - Dr. Manuel Barros Borgono - PPDS
    Providencia, Región-MetropolitanadeSantiago 7500587, Chile
  • BIOCINETIC Ltda
    Santiago, Región-MetropolitanadeSantiago 8320000, Chile
  • Centro de Investigacion de Enfermedades Respiratorias e inmunologicas
    Viña del Mar, Valparaiso 2520000, Chile
  • Clinical Center Zagreb - Oncology - Salata 7 - PPDS
    Zagreb, City of Zagreb 10000, Croatia
  • Polyclinic Bonifarm
    Zagreb, City of Zagreb 10000, Croatia
  • Clinical Hospital Centre Osijek
    Osijek, 31000, Croatia
  • University Hospital of Split-Spinciceva 1
    Split, 21000, Croatia
  • Hopital Emile Muller
    Mulhouse, Haut-Rhin 68100, France
  • CHU de Bordeaux - Hôpital Saint-André
    Bordeaux, 33000, France
  • CHU de Brest - Hôpital La Cavale Blanche
    Brest, 29609, France
  • AP-HP - Hôpital Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67200, France
  • Rheumazentrum Prof. Dr. med. Gunther Neeck-Standort Bad Doberan
    Bad Doberan, Mecklenburg-Vorpommern 18209, Germany
  • Rheumazentrum Greifswald
    Greifswald Hansestadt, Mecklenburg-Vorpommern 17493, Germany
  • DRK Gemeinnützige Krankenhaus GmbH Sachsen - DRK Krankenhaus Chemnitz-Rabenstein
    Chemnitz, 09117, Germany
  • MVZ Rheuma
    Hamburg, 20095, Germany
  • Olympion General Clinic
    Kato Sychena Patras, Achaïa 264 43, Greece
  • Naval Hospital of Athens
    Athens, Attica 115 21, Greece
  • Laiko General Hospital of Athens
    Athens, Attica 115 27, Greece
  • University General Hospital of Larissa
    Larissa, Larisa 411 10, Greece
  • Euromedica Kianous Stavros
    Thessaloniki, 546 36, Greece
  • Bekes Varmegyei Kozponti Korhaz
    Gyula, Bekes County 5700, Hungary
  • Vasarhelyi Sarkanyfu Kft.
    Hódmezővásárhely, Csongrád megye 6800, Hungary
  • Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet - Albert Flórián út 5-7
    Budapest, 1097, Hungary
  • Meir Medical Center
    Kfar Saba, Central District 44281, Israel
  • The Chaim Sheba Medical Center - PPDS
    Ramat Gan, 5262100, Israel
  • AUSL di Reggio Emilia - IRCCS - Arcispedale Santa Maria Nuova
    Reggio Emilia, Emilia-Romagna 42121, Italy
  • Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia
    Udine, Friuli Venezia Giulia 33100, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico
    Rome, Lazio 00128, Italy
  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
  • A.O.U. Città della Salute e della Scienza di Torino
    Turin, Piedmont 10126, Italy
  • AOU Policlinico Gaspare Rodolico-San Marco - Presidio Ospedaliero San Marco
    Catania, Sicily 95121, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Tuscany 50134, Italy

Showing the first 100 of 206 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jul 2026, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Jan 24, 2024
Primary completionActual
Jul 23, 2026
CompletionActual
Aug 17, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06104124
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Jan 24, 2024
Primary completion
Jul 23, 2026
Completion
Aug 17, 2026
Last update
Oct 29, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion